Taysha Gene Therapies Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Taysha Gene Therapies Inc 's ROA in the second quarter of 2026?
Taysha Gene Therapies Inc recorded a cumulative net loss of $-150 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -42%.

However, within the Healthcare sector 503 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3789, from total ROA ranking in the first quarter of 2026 at 4428.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	43.84 %	117.08 %	124.96 %	79.45 %	69.56 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-150	-130	-109	-100	-93
Return On Assets (TTM)	-42 %	-40.53 %	-38.94 %	-43.03 %	-46.87 %
TSHA's Total Ranking	# 3789	# 4428	# 3925	# 4029	# 4168
Total Assets (TTM) in million	471	300	343	311	327
Seq. Total Assets Change	56.71 %	-12.52 %	10.48 %	-5.03 %	136.5 %
Seq. Net Income Change	-	-	-	-	-

TSHA's 5 Years Annual ROA >> Back to TSHA Management Effectiveness >> Compare TSHA ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 69
Sector	# 504
Overall	# 3778

Return On Assets Statistics
High	Average	Low
-12.9 %	-72.18 %	-170.26 %
(Sep 30 2024)		(Sep 30 2023)

Financial Statements
Taysha Gene Therapies Inc 's Assets	$ 471 million	TSHA's Balance sheet
Taysha Gene Therapies Inc 's Income	$ -47 million	Quarterly TSHA's Income Statement
TSHA's Income by Division		See TSHA's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	124.96 %	-7.33 %	40.31 %	-45.14 %	-17.35 %
Total Assets in million	343	153	165	117	214
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-109	-89	-112	-166	-175
Annual Return On Assets	-31.75 %	-58.51 %	-67.74 %	-141.43 %	-81.57 %

TSHA's 5 Years Annual ROA >> Back to TSHA Management Effectiveness >> Compare TSHA ROA to its Competitors

More Return On Assets Ratios
TSHA's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
TSHA's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for TSHA's Competitors
Subscribers only: Roa for Taysha Gene Therapies Inc 's Suppliers
Subscribers only: Return On Assets for TSHA's Customers

You may also want to know
TSHA's Roi	TSHA's Inventory Turnover Ratio	TSHA's Growth Rates	TSHA's Dividend Comparisons
	TSHA's Profitability Ratios	TSHA's Asset Turnover Ratio	TSHA's Dividend Growth
TSHA's Roe	TSHA's Valuation Ratios	TSHA's Financial Strength Ratios	TSHA's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-05T00:18:00+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.